Subscribe to RSS
Therapeutic Approach Against 2019-nCoV by Inhibition of the ACE-2 receptor
The continued spread of the 2019 novel coronavirus (2019-nCoV) has prompted global concern. The formal name given to 2019-nCoV by the World Health Organization is COVID-19, while the International Committee on Taxonomy has named it severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Due to this viral attack, nations around the world have issued lockdown restrictions. Presently, there is no effective way to control the spread of 2019-nCoV, except through social distancing and hygienic activities. World-class scientists and researchers are trying to develop vaccines and medicines that will cure this deadly viral disease and control its spread. Our aim in presenting this article is to provide an easy therapeutic approach that effectively combats deadly viral diseases, such as COVID-19, with minimal intervention and effort. Different Ayurvedic therapeutic agents (Curcuma longa L, green tea, and Piper nigrum) inhibit the entry of viruses in the host cell and the transmission of pathogens, while improving immunity. Curcumin and piperine (1-piperoylpiperidine) interact with each other and form a π–π intermolecular complex that enhances the bioavailability of curcumin by inhibition of glucuronidation of curcumin in the liver. Two molecules, curcumin and catechin, bind directly to the receptor-binding domain of the S-protein and the angiotensin-converting enzyme 2 receptor of the host cell, by which these molecules inhibit the entry of viruses in the host cell. As a result, the animal host will survive the infection.
Received: 04 September 2020
Received: 27 September 2020
Accepted: 28 September 2020
23 December 2020 (online)
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Cyranoski David. Profile of a scientists are quickly piecing together how the new coronavirus operates, where it came from and what it might do next—but pressing questions remain. Nature 2020; 581: 22-26
- 2 Liying D, Shashu H, Jianjun G. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discoveries & Therapeutics 2020; 14: 58-60
- 3 Zhou P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; DOI: 10.1038/s41586-020-2012-7.
- 4 Rolling updates on corona virus disease (COVID-19) https://www.who.int/emergencies/diseases/novel-coronavirus-019/events-as-they-happen
- 5 Pengfei S, Xiaosheng L, Chao X. et al. Understanding of COVID-19 based on current evidence. Jou Med Virol 2020; DOI: 10.1002/jmv.25722.
- 6 Shulla A, Sargent TH, Subramanya G. et al. Transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. Jou of Virology 2011; 85: 873-882
- 7 Shiv K, Roop K, Mohammad M. et al. Turmeric (Curcuma longa L.): A promising spice for phytochemical and pharmacological activities. International Journal of Green Pharmacy 2013; 7: 85
- 8 Priya NC, Kumar PS. Antiviral activities and cytotoxicaty assay of seed extracts of Piper longum and Piper nigrum on human cell lines. Int J Pharm Sci Rev Res 2017; 44: 197-202
- 9 Joshi DR, Shrestha AC, Adhikari N. A review on diversified use of the king of spices: Piper nigrum (Black Paper). IJPSR 2018; 9: 4089-4101
- 10 Cynthia L, Qiongqiong Z, Yingzhu L. et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020; 6: 315-331
- 11 Zheng YY, Ma YT, Zhang JY. et al. COVID-19 and the cardiovascular system. DOI: 10.1038/s41569-020-0360-5.
- 12 Firas A, Mazhar S, Al Z. et al. SARS-CoV-2 and coronavirus disease 2019: What we know so far. Pathogens 2020; DOI: 10.3390/pathogens9030231.
- 13 Joong SS, Jin HK, Hyun YC. et al. Irreversible inhibition of CD13/Aminopeptidase N by the antiangiogenic agent curcumin. Chemistry & Biology 2003; 10: 695-704
- 14 Reguera J. Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies. PLoS Pathog 2012; DOI: doi: 10.1371/journal.ppat.1002859.
- 15 Fang Li. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016; 3: 237-261
- 16 Aleksi S, Kvetoslava V, Petr B. et al. Quaternary benzo[c]phenanthridine alkaloidsas inhibitors of aminopeptidase N and dipeptidyl peptidase IV. Phytother Res 2002; 16: 84-87
- 17 Thomas MG, Michal JB. Coronavirus spike proteins in viral entry and pathogenesis. Virology 2002; 279: 371-374
- 18 Lingshu W. et al. Evaluation candidate vaccine approaches for MERS-CoV. Nature Communications 2015; 6: 7712 DOI: 10.1038/ncomms8712.
- 19 Kenneth EB, Zakir KJ, Duo YC. et al. Angiotensin-converting enzyme in innate and adaptive immunity. Nat Rev Nephrol 2018; 14: 325-336
- 20 Emily LC, Eng EO, Chin YL. et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerging Infectious Diseases 2004; 10: 581-586
- 21 Shobal G, David J, Thangam J. et al. Influence of piperine on the pharmacokinetics of curcuminin animals and human volunteers. Planta Medica 1998; 64: 353-356
- 22 Atala BJ, Namrata K, Vinayak N. et al. Catechin and curcumin interact with corona (2019-nCoV/SARS-CoV2) viral S protein and ACE2 of human cell membrane: insights from Computational study and implication for intervention. 2020; DOI: 10.21203/rs.3.rs-22057/v1.
- 23 Song JM. Anti-infective potential of catechins and their derivatives against viral hepatitis. ClinExp Vaccine Res 2018; 7: 37-42
- 24 Shinojima N, Yokoyama T, Kondo Y. et al. Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin induced Autophagy. Autophogy 2007; 3: 635-637
- 25 Vaishali MP, Sukanya D, Krishnan B. Quantum chemical and docking insights into bioavailability enhancement of curcumin by piperine in pepper. J Phy Chem A 2016; 120: 3643-3653